GANX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.7M
-12.6%
5.4M
+19.9%
4.5M
-6.7%
4.8M
-6.0%
5.1M
R&D
2.1M
-22.6%
2.8M
+17.7%
2.3M
-17.6%
2.8M
+3.3%
2.8M
SG&A
2.5M
-1.8%
2.6M
+22.3%
2.1M
+9.4%
1.9M
-16.9%
2.3M
Operating Income
-4681652
+12.6%
-5353545
-19.9%
-4466023
+6.7%
-4785777
+6.0%
-5089526
EBITDA
-4654482
+12.7%
-5332242
-20.2%
-4437782
+6.8%
-4762960
+6.0%
-5067198
Net Income
-4675571
+16.6%
-5608732
-23.6%
-4537581
+14.1%
-5284373
+9.0%
-5809087
EPS (Basic)
$-0.11
+15.4%
$-0.13
-8.3%
$-0.12
+20.0%
$-0.15
+21.1%
$-0.19
EPS (Diluted)
$-0.11
+15.4%
$-0.13
-8.3%
$-0.12
+20.0%
$-0.15
+21.1%
$-0.19
Shares (Diluted)
42.9M
+1.5%
42.2M
+11.6%
37.8M
+8.1%
35.0M
+15.3%
30.3M
Gain Therapeutics (GANX) โ€” Financials